GGrantIndex
← Search

Planning & Evaluation

$88,857P30FY2015CANIH

Sloan-Kettering Inst Can Research, New York NY

Investigators

Linked publications, trials & patents

Trial NCT03699631Trial NCT02595918Trial NCT02417701Trial NCT02219737Trial NCT02152995Trial NCT01979523Trial NCT01947023Trial NCT01902160Trial NCT01705340Trial NCT01643278Trial NCT01638546Trial NCT01587352Trial NCT01585805Trial NCT01326702Trial NCT01281865Trial NCT01196416Trial NCT01154452Trial NCT01143402Trial NCT01119599Trial NCT01051557Trial NCT01026623Trial NCT01016015Trial NCT00957905Trial NCT00866177Trial NCT00729157Trial NCT00639509Trial NCT00601692Trial NCT00589472Trial NCT00570401Trial NCT00567229Trial NCT00550628Trial NCT00541034Trial NCT00528450Trial NCT00522301Trial NCT00521014Trial NCT00519974Trial NCT00514254Trial NCT00498927Trial NCT00483678Trial NCT00474994Trial NCT00471679Trial NCT00471601Trial NCT00470574Trial NCT00470470Trial NCT00462982Trial NCT00462501Trial NCT00459875Trial NCT00458705Trial NCT00453310Trial NCT00450827Trial NCT00416351Trial NCT00404365Trial NCT00398138Trial NCT00397904Trial NCT00369174Trial NCT00354679Trial NCT00334893Trial NCT00324480Trial NCT00245102Trial NCT00104845Trial NCT00090337Trial NCT00089245Trial NCT00087009Trial NCT00072345Trial NCT00072319Trial NCT00070057Trial NCT00067015Trial NCT00062374Trial NCT00059891Trial NCT00058253Trial NCT00054132Trial NCT00046917Trial NCT00040898Trial NCT00040872Trial NCT00039286Trial NCT00037011Trial NCT00036933Trial NCT00028730Trial NCT00024258Trial NCT00023764Trial NCT00020891Trial NCT00016146Trial NCT00014534Trial NCT00014469Trial NCT00008294Trial NCT00008242Trial NCT00006044Trial NCT00004245Trial NCT00004066Trial NCT00003923Trial NCT00003819Trial NCT00003173Trial NCT00003023Trial NCT00002981Trial NCT00002930Trial NCT00002766Trial NCT00002738Trial NCT00002718Trial NCT00002663Trial NCT00002558

Abstract

MSKCC relies on the counsel of outside advisors, represented by its Board of Scientific Consultants (BSC), the guidance of its Board of Overseers and Managers, as well as many internal planning processes to support the planning and evaluation of the research programs and core facilities at the Center. MSKCC has used the guidance it has received to develop and execute its initiatives for research and clinical expansion. During the past five years, the BSC has reviewed the research in many areas, including the Developmental and Stem Cell Biology Program, the Molecular Structure Program, the Prevention, Control and Population Research Program (now the Survivorship, Outcomes, and Risk Program), along with its efforts in Immigrant Health and Cancer Disparities, the Immunology and Transplantation Program, the Imaging and Radiation Sciences Program, the Cancer Biology and Experimental Pathology Program, Experimental Therapeutics, and disease-specific components of the Clinical Research Program. The BSC has also reviewed some of the newly recruited junior investigators and the training programs that bring outstanding students to train in MSKCC's laboratories. In addition to the BSC, the senior leaders receive strategic counsel from the MSKCC Board of Overseers and Managers to provide both community and financial stewardship as well as tactical advice on Center policies. A Task Force was also created to internally evaluate the Cores' infrastructure, and several improvements have been enacted. Through input from program members and the Associate Directors, further collaborative research centers that foster interactions between laboratory and clinical investigators have also been established. The recommendations made by the BSC and other planning groups have led to program reorganizations, new faculty recruitments, shared resource development, and facility expansions.

View original record on NIH RePORTER →
Planning & Evaluation · GrantIndex